Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
Novo Nordisk has made its smart insulin pens available in the UK ... The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an increasingly competitive insulin market ...
Eli Lilly announced at the beginning of March ... including pre-filled insulin pens and vials. The company suggested that this would mean patients would pay $25-35 for their insulin.
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.
Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...
1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...